Kornimate/medical-research-clean huggingface dataset:
investigating how the brain processes different experiences

Conditions: Anxiety

Summary: the goal of this clinical trial is to test the efficacy of an app-based program in reducing anxiety and exploring associated changes in brain activity.

the main question\[s\] it aims to answer are: primary aim: confirm that the conscious experience of open/closed correlates with p/pcc activation/deactivation. secondary aim: determine if changes in p/pcc activity predict clinical outcomes (gad-7 scores) in individuals with moderate to severe anxiety after using an app. participants may be asked to: * complete a zoom interview * complete online surveys at baseline and 2 months post-treatment initiation * complete mris at baseline and 2 months post-treatment initiation * wear a smartwatch and answer daily questions about their anxiety * use an app daily

Eligibility criteria:
inclusion criteria: 1. 18 - 65 years 2. able to travel to brown university for research assessment 3. able to speak english because all study activities will be conducted in english. 4. gad-7 ≥ 10 5. owns a smartphone exclusion criteria: 1. if using psychotropic medication - not on a stable dosage at least 6 weeks 2. as needed (i.e., prn) benzodiazepine use 3. psychotic disorder (e.g., bipolar disorder, schizophrenia, schizoaffective disorder, psychosis) 4. mri contraindications 5. claustrophobia 6. recreational drug use past 2 weeks 7. alcohol abuse 8. pregnancy or plans to become pregnant 9. cohabiting with a study participant 10. weight ≥ 300 lbs (due to inability to fit in scanner)

Keywords: anxiety mindfulness mri cell phone
oral health in children and adolescents with obesity and normal weight

Conditions: Pediatric Obesity; Pediatric Dentistry

Summary: we aimed to compare the oral health status (dmft/dmft index, idcas-ii, bewe, plaque index, gingival index, probing depth) between normal-weight (nw) and obese (ow) children/adolescents. 82 participants aged 6-16 years were concluded in this cross-sectional study. the children/adolescents were classified according to the body mass index (bmi): nw (n=41) and ow (n=41). caries experience was assessed by the international caries detection and assessment system (icdas-ii), decay, missing, filling teeth (dmft) for the primary teeth and (dmft) for the permanent teeth, erosive tooth wear using basic erosive wear examination (bewe), plaque index (pi) and gingival index (gi), probing depth (pd).

also, the relationship between procalcitonin (pct), c-reactive protein (crp), parathormone (pth), and 25(oh)d blood biochemistry and oral health was evaluated in obese children/adolescents.

Eligibility criteria:
inclusion criteria: 6-16 years obesity children and adolescents * 6-16 years healthy children and adolescents exclusion criteria: * infection, * diabetes, leukemia, asthma, bronchitis, cognitive neuromotor disorder, hormonal disease

Keywords: dental caries periodontal health children obesity erosive tooth wear
metro atlanta heart disease study - ii (mahds ii)

Conditions: African Americans With Hypertension.

Summary: a 12-week treatment/control trial was implemented to assess the effects of a multi component lifestyle program on improvements in body mass index, weight, perceived stress and blood pressure in african american men and women who were at increased risk for cardiovascular disease. it was hypothesized that treatment group would experience significant improvements when compared to the control group.


Eligibility criteria:
inclusion criteria: african american men and women aged \>21 with elevated blood pressure and excess body weight who resided in metro atlanta, ga. - exclusion criteria: individuals with normal blood pressure and body weight, as well as those residing outside of metro atlanta, ga. individuals with psychological conditions were also excluded. -

Keywords: high blood pressure, hypertension, african americans, perceived stress
detection of cannabis impairment with an eye tracker

Conditions: Cannabis Intoxication

Summary: cannabis is one of the widely used psychoactive substances in the world. with increasing legalization, the prevalence of driving under the influence of cannabis will undoubtedly rise. at present, roadside detection of cannabis intoxication is largely dependent on drug recognition experts who rely on changes in eye movements when impaired. in this regard, use of eye trackers can help to detect impairment in drivers. the purpose of the present study is to determine the feasibility of the use of eye trackers in detecting impairment in participants who smoked a cannabis cigarette.

participants will attend one study session after determination of eligibility. during this session, they will smoke a cannabis cigarette with 12.5% thc prior to driving a simulator. driving will be assessed prior to smoking cannabis and at 7 time points after smoking cannabis. eye tracking measures will also be taken while driving after smoking cannabis. blood will be drawn for determination of levels of the psychoactive substance thc and its metabolites. saliva tests, urine tests and subjective tests will also be performed at various times points after smoking cannabis.

Eligibility criteria:
inclusion criteria: * weekly use of cannabis (1 to 4 days per week) confirmed by urine point-of-care testing; * 19-26 years of age; * holds a class g or g2 ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months; * willing to abstain from using alcohol for 48 hours and cannabis for 72 hours prior to the study session; * willing to abstain from all other drugs not prescribed for medical purposes for the duration of the study; * provides written and informed consent. exclusion criteria: * urine toxicology screens negative for cannabis upon eligibility assessment; * diagnosis of severe medical or psychiatric conditions; * females: pregnancy or breastfeeding; * meets criteria for alcohol or substance dependence (current or lifetime) (dsm-iv); * is a regular user of medications that affect brain function (i.e., antidepressants, benzodiazepines, stimulants); * first-degree relative diagnosed with schizophrenia.
trial of high-dose urso in primary sclerosing cholangitis

Conditions: Primary Sclerosing Cholangitis

Summary: this is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for patients with primary sclerosing cholangitis (psc). the average duration of follow-up will be approximately five years with important clinical endpoints such as death, eligibility for liver transplantation, changes in histology and cholangiogram as well as liver biochemistries and quality of life data collected.


Eligibility criteria:
* chronic cholestatic disease of at least six months' duration. * serum alkaline phosphatase at least 1 ½ times the upper limits of normal. * retrograde, operative, percutaneous, or magnetic resonance cholangiography demonstrating intrahepatic and/or extrahepatic biliary duct obstruction, beading, or narrowing consistent with psc within one year of the study entry. * liver biopsy in the previous one year which is available for review and compatible with the diagnosis of psc. compatible biopsy features include fibrous cholangitis, ductopenia with periportal inflammation and biliary fibrosis.

Keywords: urso psc
circuit-based deep brain stimulation for parkinson's disease p1a2&3 catalyst

Conditions: Parkinson Disease

Summary: this study will help us better understand how the brain works in people with parkinson's disease (pd). pd is a brain disease that gets worse over time, and affects over 10 million people world-wide. a common treatment for pd is deep brain stimulation (dbs). to improve dbs therapy for pd, we need a deeper understanding of how the different parts of the brain work together in pd, and how this relates to movement and thinking problems that people with pd experience. we may be able to use the results of this study to improve dbs treatments in the future.

parkinson's disease (pd) is a progressive neurodegenerative disease affecting over 10 million people world-wide. it can be a debilitating disorder and although studied for decades, the physiological changes in the basal ganglia thalamocortical (bgtc) circuit that underlie its development remain under debate. deep brain stimulation (dbs) of the subthalamic nucleus (stn) and internal globus pallidus (gpi) has been a highly effective therapy for many patients with pd, however, the results have been highly variable and may be associated with cognitive compromise in some patients. to advance dbs therapies for pd we require a deeper understanding of the local and network-wide circuit dynamics and their relationship to motor signs and cognitive function. this understanding will provide the rationale for optimizing stn and gpi dbs, targeting specific regions within the stn and gpi, and development of patient-specific dbs based on the patients' motor signs and cognitive profile

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd * surgery at umn to implant dbs system with directional lead(s) and multiple independent current control ipg is planned as part of routine clinical care * at least 21 years old * existing or planned 7t brain imagery exclusion criteria: * other significant neurological disorder * history of dementia * patients with post-operative complications or adverse effects (e.g. on stimulation dystonias) that affect patient safety or confound the experiment will be excluded from further study * pregnant women * known radiation exposure within the last year that is determined to be unsafe when compounded with the expected radiation dose from intraoperative fluoroscopy to place ecog strip
optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer study

Conditions: Venous Thrombosis; Neoplasms; Anticoagulant

Summary: the purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.

venous thromboembolism (vte), including pulmonary embolism (pe) and deep vein thrombosis (dvt), is a major health problem in the world. there have been many clinical studies evaluating pe and/or proximal dvt, although data on isolated distal dvt (iddvt) has been quite limited. however, iddvt was reported to account for about half of all the diagnoses of dvt detected on ultrasound in daily clinical practice, and optimal management strategies for these patients are becoming clinically more relevant. the current american college of chest physicians (accp) guidelines suggest the same approach for iddvt patients with cancer as proximal dvt patients with cancer. however, whether anticoagulation therapy should be continued indefinitely remains uncertain and the duration of treatment in these patients might vary widely in daily clinical practice. recently, some observational studies reported that iddvt patients with cancer have a high risk of vte recurrence, suggesting the benefit of prolonged anticoagulation therapy. in this open-label, superiority trial, we will randomly assign iddvt patients with active cancer to receive either edoxaban for 3 months (short doac group) or edoxaban for 12 months (long doac group).

Eligibility criteria:
inclusion criteria: * patients with newly found isolated distal deep vein thrombosis * patients complicated with active cancer * patients who are scheduled to be treated by anticoagulation therapy. exclusion criteria: * patients with anticoagulation therapy for the index event before 10 days of allocation. * patient under anticoagulation therapy for the purpose of other than the index event. * patients with thrombolysis therapy or ivc filter at the index event. * patients with creatinine clearance less than 30 ml/min. * patients who are expected to have a life prognosis of 3 months or less. * patients with pulmonary embolism. * patients who are not appropriate for the participation of the study.

Keywords: venous thrombosis neoplasms anticoagulant
erector spinae plane block for uncomplicated renal colic

Conditions: Renal Colic; Kidney Stone

Summary: this research study is to determine how well the erector spinae plane block (espb) works for kidney stone pain and any possible side effects.


Eligibility criteria:
inclusion criteria: * imaging confirmation of urolithiasis on the index encounter or prior encounter within 7 days * patient received one dose of parenteral pain medication in the emergency department (ed) exclusion criteria: * pregnancy or breastfeeding * prisoner or incarcerated individual * therapeutic anticoagulation or coagulopathy. * active treatment for urinary tract infection (either acute infection or chronic therapy) * prior spinal surgery in the thoracic region * allergy to local anesthetic or prior local anesthetic * soft tissue infection overlying the injection site * positive for coronavirus * inability to communicate verbally or read/write in english * currently taking strong cyp1a2 inhibitor (fluvoxamine, amiodarone, fluoroquinolones, etc.) * glucose-6-phosphate dehydrogenase deficiency (g6pd)

Keywords: erector spinae plane block emergency department ropivacaine
effects of gastrostomy on amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: results about effects of symptomatic treatment on qol appears conflicting in als patients. moreover no clear effects of gastrotomy have be shown on survival. prospective study on effect of tube feeding, qol and survival is performed in 17 teaching hospitals in france (observational study)

following data have been recorded each three months: qol (mos-sf 36 and alsaq), bodily mass index, testing and als-frs scale, functional respiratory measures, impedance analysis, and the time for tube feeding procedure, the conditions of the acceptance and side-effects of gastrotomy

Eligibility criteria:
inclusion criteria: * patients \> 18 years-old * als certain or probable * vital capacity (respiratory) \> 70 % * under riluzole exclusion criteria: * als in family * other conditions affected survival and qol * cognitive impairment

Keywords: gastrostomy quality of life
prospective trial evaluating the effect of closed suction drainage versus straight drainage after distal pancreatectomy

Conditions: Pancreatic Fistula

Summary: a very common complication following distal pancreatectomy is leakage from the pancreas, or what is called a pancreatic fistula. we hypothesize that operative drains which create suction may contribute to the development of leakage from the pancreas. this study evaluates the effect of using non-suctioning drains to prevent the development of this complication.

the most common complication following distal pancreatectomy is the developement of leakage from the remaining pancreas gland, which results in significant morbidity. most surgeons leave dains at the time of surgery to prevent complications from pancreatic leakage. however, we hypothesize that drains which create continous negative pressure may contribute to the development of a pancreatic fistula. this study randomizes patients to suctioning versus non-suctioning drains. the primary endpoint is the development of pancreatic fistuale, as defined by the international study group of pancreatic surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing distal pancreatectomy at johns hopkins hospital exclusion criteria: * children \<18 years old, pregnant women, adults lacking capacity to consent, non-english speakers, and prisoners.

Keywords: pancreatic fistula
curcumin biomarker trial in head and neck cancer

Conditions: Head and Neck Cancer

Summary: there is considerable evidence that turmeric consumption may have a protective effect against cancer progression. the purpose of this study is to examine the short-term effects of supplementation with a turmeric extract, curcumin c3 complex®, on biomarkers of head and neck squamous cell carcinoma (hnscc).

this is an open label, exploratory biomarker trial of the food substances curcumin c3 complex® in subjects with newly diagnosed hnscc. curcumin, a novel safe nutritional interventional agent has exciting potential usage as a preventive/adjuvant agent, and prevents tumor formation by inhibiting an important molecular pathway that is shown to cause cancer progression, which we will test as a tumor marker in this clinical trial. the primary objective is to evaluate biomarker response of hnscc patients to the food substances curcumin c3 complex®. this will be done by comparing post-intervention values to baseline values. in addition, we will determine the levels of curcumin and its metabolites in tumor and adjacent tissue.

Eligibility criteria:
inclusion criteria: * subjects with newly diagnosed head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx and have at least one accessible tumor * subjects willing to undergo tumor biopsies * subjects willing to refrain from nonsteroidal anti-inflammatory drugs (nsaids) * eastern co-operative oncology group (ecog) status of 0-3 * absolute neutrophil count ≥ 1500/mm³, hgb ≥ 10g/dl and platelet count ≥ 150,000 mm3 * adequate renal function: serum creatinine ≤ 1.5 × upper limit of normal (uln). adequate hepatic function: total bilirubin ≤ 1.5 × uln, aspartate aminotransferase (ast) or alanine aminotransferase (alt) ≤ 2.0 × uln * signed and dated institutional review board approved informed consent form before any protocol specific procedures are performed * willingness of subjects who are not surgically sterile or postmenopausal to use reliable methods of birth control for the duration of the study and for 2 weeks after last dose of study drug * no consumption of curcumin-rich foods to subject's knowledge within the previous 48 hours * age ≥ 18 years to ≤ 90 years exclusion criteria: * subjects receiving anticoagulation therapy * known hypersensitivity to curry or black pepper * prior cancer therapy in the last 30 day * concurrent chemotherapy or radiation * severely immunocompromised subjects * subjects known to be hiv positive * any major illness that, in the investigator's judgment, will substantially increase the risk asociated with the subject's participation in the study * pregnant or nursing women * unwillingness or inability to comply with required study visits and procedures in this protocol

Keywords: cancer
evaluation of oct measurements

Conditions: Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma

Summary: the purpose of the study is to repeatability, reproducibility and agreement of eye measurements in retina and glaucoma patients.

the purpose of the study is to repeatability, reproducibility and agreement of eye measurements in retina and glaucoma patients using oct technology. there will be a series of measurements acquired from one eye on at least 2 different oct devices. all testing will be completed in one visit.

Eligibility criteria:
inclusion criteria: inclusion criterea: * at least 18 years of age * able and willing to provide consent * willing to complete the required examinations and visits * best corrected visual acuity equal or better than 20/100 * retina subject must have clinical diagnosis of retinal pathology * glaucoma subjects must have clinical diagnosis of glaucoma exclusion criteria: * unable to complete the required examinations and visits * poor oct image quality as a result of media opacity, extreme refractive error or pathologies in the anterior segment * confounding pathology requiring surgical treatment or medical intervention
virtual reality and subjective tinnitus

Conditions: Tinnitus; Tinnitus, Subjective

Summary: the purpose of this study is to test if virtual reality immersion has the potential to significantly decrease subjective tinnitus intrusiveness when compared to standard care.

this is a randomised controlled study aimed at further validating the use of virtual reality in the field of subjective tinnitus management. indeed, earlier results have suggested that this innovative strategy has the potential to be as efficient as a cognitive and behavioural therapy. before the sessions, an automated tinnitus matching procedure will help create a sound similar to the tinnitus percept ("tinnitus avatar"). during the sessions (8 sessions; 30 minutes), the "tinnitus avatar" will be displayed auditorily but also visually - as a sparkling spot - in a variety of virtual 3d auditory and visual environments. in these virtual environments the patients will be given the possibility to voluntarily control and manipulate the "tinnitus avatar" by the means of a wand on top of which the sound and the sparkling will be attached. they will also be able to freely navigate in the virtual scenes where environmental sound will be displayed. then the patients will be able to displace at will the "tinnitus avatar" in their peri-personal space or mask it by getting close to sounds they may encounter in the virtual scenes. it is supposed that regaining and training a capacity of interaction with the "tinnitus avatar" as if it were a standard sound will help recalibrate the attentional processes involved in tinnitus perception and then to decrease tinnitus intrusiveness.

Eligibility criteria:
inclusion criteria: * age \> 18 years and \< 75 years, * french speaking and ability to understand multidimensional questionnaires, * subjective tinnitus of peripheral origin (middle or inner ear auditory nerve) * subjective tinnitus stable and chronic (lasting for more than 6 months) * subjective tinnitus that can be characterized by tinnitus matching * normal hearing or moderate hearing loss exclusion criteria: * fluctuating tinnitus, * unilateral or bilateral severe or profound hearing loss, * claustrophobia, visual, impairment, vertigo or dizziness, chronic headache or any other condition contraindicating virtual immersion * psychiatric condition requiring immediate management * pregnant or breastfeeding women * protected adults (including individual under guardianship by court order) * persons deprived of their liberty by judicial or administrative decision

Keywords: subjective tinnitus virtual reality cognitive behavioral therapy